EMA Recommends Extension of Indications for Pembrolizumab
Extension concerns the treatment of classical Hodgkin lymphoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
Efficacy was demonstrated in the VISION study
Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab
Application concerned the use in combination with platinum-based therapy in previously untreated metastatic urothelial cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Selinexor
It is intended for the treatment of relapsed and refractory multiple myeloma
Majority of Patients With Cancer Are Willing To Be Vaccinated Against COVID-19
Results from a cross-sectional survey in France
EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib
It is intended for second-line treatment of advanced cholangiocarcinoma with a FGFR2 fusion or rearrangement
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the CHECKMATE-9ER study
FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed Light Chain Amyloidosis
Evidence for efficacy is based on the results from the ANDROMEDA study
Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early Breast Cancer
The Cancer and Aging Research Group-Breast Cancer score was developed and validated to predict grade 3-5 toxicity in elderly patients with stage I-III disease
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas
Evidence for efficacy is based on the results from the DESTINY-Gastric01 study
FDA Approves Crizotinib for Children and Young Adults with Relapsed or Refractory, Systemic ALK-positive Anaplastic Large Cell Lymphoma
The safety and efficacy of crizotinib is not established in older adults with same disease
GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations
The analysis also illustrates differences according to sex and ethnic group